ReviewCells2021
Gut Microbiota-Related Cellular and Molecular Mechanisms in the Progression of Nonalcoholic Fatty Liver Disease.
Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06585982 (Gut Microbiota Profile Analysis and Randomized Controlled Trials), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Gut Microbiota Profile Analysis and Randomized Controlled Trials (RCT) Study of the Effect of Synbiotics on Insulin and TNF-α in Metabolic Dysfunction -Associated Fatty Liver Disease (MAFLD)
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- A Low Glycemic Index Mediterranean Diet Combined with Aerobic Physical Activity Rearranges the Gut Microbiota Signature in NAFLD Patients.Nutrients · 2022Trial
- Gut microbiota, liver disease, and perioperative anesthesia: interactions, risks, and therapeutic opportunities.Frontiers in cellular and infection microbiology · 2025Review
- Association of Gut Microbiota-Derived Short-Chain Fatty Acids With Persistent Elevated Serum Transaminase Levels in Normal Weight and Obesity: A Pilot Study.Journal of nutrition and metabolism · 2025Article
- Gut microbiota dysbiosis in alcoholic fatty liver disease: distinct microbial communities and biochemical alterations.American journal of translational research · 2025Article
- Article
- Impact of Combination Antiretroviral Treatment on Liver Metabolic Health in HIV-Infected Persons.Viruses · 2023Review
- Secondary bile acids improve risk prediction for non-invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease.Alimentary pharmacology & therapeutics · 2023Article
- Gut-Liver Axis and Non-Alcoholic Fatty Liver Disease: A Vicious Circle of Dysfunctions Orchestrated by the Gut Microbiome.Biology · 2022Review
- Microbiome-Based Metabolic Therapeutic Approaches in Alcoholic Liver Disease.International journal of molecular sciences · 2022Review
- Premenopausal Syndrome and NAFLD: A New Approach Based on Gender Medicine.Biomedicines · 2022Review
- The Interaction between the Gut Microbiome and Bile Acids in Cardiometabolic Diseases.Metabolites · 2022Review
- Male zooid extracts ofFrontiers in cellular and infection microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Nonalcoholic fatty liver disease (NAFLD) is one of the most common and increasing liver diseases worldwide. NAFLD is a term that involves a variety of conditions such as fatty liver, steatohepatitis, or fibrosis. Gut microbiota and its products have been extensively studied because of a close relation between NAFLD and microbiota in pathogenesis. In the progression of NAFLD, various microbiota-related molecular and cellular mechanisms, including dysbiosis, leaky bowel, endotoxin, bile acids enterohepatic circulation, metabolites, or alcohol-producing microbiota, are involved. Currently, diagnosis and treatment techniques using these mechanisms are being developed. In this review, we will introduce the microbiota-related mechanisms in the progression of NAFLD and future directions will be discussed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.